File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The role of different viral biomarkers on the man- agement of chronic hepatitis B

TitleThe role of different viral biomarkers on the man- agement of chronic hepatitis B
Authors
KeywordsChronic hepatitis B
Hepatitis B core antigen
Treatment outcome
Viremia
Issue Date1-Apr-2023
PublisherKorean Association for the Study of the Liver
Citation
Clinical and Molecular Hepatology, 2023, v. 29, n. 2, p. 263-276 How to Cite?
Abstract

Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess viral activity. In this review article, we summarize the relevant data of how antiviral therapies impact viral biomarkers, and discuss their potential implications. Viral nucleic acids including hepatitis B virus (HBV) double-stranded deoxy-ribonucleic acid (DNA) and to a lesser extent, pre-genomic RNA, are readily suppressed by nucleos(t)ide analogues (NUCs). The primary role of these markers include risk prediction for hepatocellular carcinoma (HCC) and risk stratification for partial cure, defined as off-therapy virological control, or functional cure, defined as hepatitis B surface antigen (HBsAg) seroclearance plus undetectable serum HBV DNA for >= 6 months. Viral translational products including hepatitis e antigen, quantitative HBsAg and hepatitis B core-related antigen can be reduced by NUCs and pegylated interferon a. They are important in defining disease phase, delineating treatment endpoints, and predicting clinical outcomes including HCC risk and partial/ functional cure. As the primary outcome of phase III trials in chronic hepatitis B is set as HBsAg seroclearance, appropriate viral biomarkers can potentially inform the efficacy of novel compounds. Early viral biomarker response can help with prioritization of subjects into clinical trials. However, standardization and validation studies would be crucial before viral biomarkers can be broadly implemented in clinical use. (Clin Mol Hepatol 2023;29:263-276)


Persistent Identifierhttp://hdl.handle.net/10722/331032
ISSN
2023 Impact Factor: 14.0
2023 SCImago Journal Rankings: 3.128
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMak, LY-
dc.contributor.authorHui, RWH-
dc.contributor.authorFung, J-
dc.contributor.authorSeto, WK-
dc.contributor.authorYuen, MF-
dc.date.accessioned2023-09-21T06:52:11Z-
dc.date.available2023-09-21T06:52:11Z-
dc.date.issued2023-04-01-
dc.identifier.citationClinical and Molecular Hepatology, 2023, v. 29, n. 2, p. 263-276-
dc.identifier.issn2287-2728-
dc.identifier.urihttp://hdl.handle.net/10722/331032-
dc.description.abstract<p>Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess viral activity. In this review article, we summarize the relevant data of how antiviral therapies impact viral biomarkers, and discuss their potential implications. Viral nucleic acids including hepatitis B virus (HBV) double-stranded deoxy-ribonucleic acid (DNA) and to a lesser extent, pre-genomic RNA, are readily suppressed by nucleos(t)ide analogues (NUCs). The primary role of these markers include risk prediction for hepatocellular carcinoma (HCC) and risk stratification for partial cure, defined as off-therapy virological control, or functional cure, defined as hepatitis B surface antigen (HBsAg) seroclearance plus undetectable serum HBV DNA for >= 6 months. Viral translational products including hepatitis e antigen, quantitative HBsAg and hepatitis B core-related antigen can be reduced by NUCs and pegylated interferon a. They are important in defining disease phase, delineating treatment endpoints, and predicting clinical outcomes including HCC risk and partial/ functional cure. As the primary outcome of phase III trials in chronic hepatitis B is set as HBsAg seroclearance, appropriate viral biomarkers can potentially inform the efficacy of novel compounds. Early viral biomarker response can help with prioritization of subjects into clinical trials. However, standardization and validation studies would be crucial before viral biomarkers can be broadly implemented in clinical use. (Clin Mol Hepatol 2023;29:263-276)</p>-
dc.languageeng-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.ispartofClinical and Molecular Hepatology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectChronic hepatitis B-
dc.subjectHepatitis B core antigen-
dc.subjectTreatment outcome-
dc.subjectViremia-
dc.titleThe role of different viral biomarkers on the man- agement of chronic hepatitis B-
dc.typeArticle-
dc.identifier.doi10.3350/cmh.2022.0448-
dc.identifier.pmid36655304-
dc.identifier.scopuseid_2-s2.0-85152731517-
dc.identifier.volume29-
dc.identifier.issue2-
dc.identifier.spage263-
dc.identifier.epage276-
dc.identifier.isiWOS:000974918400007-
dc.publisher.placeSEOUL-
dc.identifier.issnl2287-2728-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats